BlossomHill Therapeutics (BLSM)


Market Price (9/22/2026): $26.13 | Market Cap: $759.9 MilSector: Health Care | Industry: Biotechnology

BlossomHill Therapeutics (BLSM)


Market Price (9/22/2026): $26.13
Market Cap: $759.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.

Trading close to highs
Dist 52W High is -0.1%, Dist 3Y High is -0.1%

Weak multi-year price returns
3Y Excs Rtn is -4.9%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -72 Mil

Key risks
BLSM key risks include [1] a total reliance on the clinical and regulatory success of its early-stage pipeline, Show more.

0 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
1 Trading close to highs
Dist 52W High is -0.1%, Dist 3Y High is -0.1%
2 Weak multi-year price returns
3Y Excs Rtn is -4.9%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -72 Mil
5 Key risks
BLSM key risks include [1] a total reliance on the clinical and regulatory success of its early-stage pipeline, Show more.

BLSM in ETFs

Weight = BLSM's share of each fund

VTI0.00%
VTWO0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/16/2026

BlossomHill Therapeutics (BLSM) stock has gained about 70% since it went public on 8/7/2026 because of the following key factors:

1. Positive Clinical Trial Data for Lead Candidate BH-30643.

BlossomHill Therapeutics announced encouraging updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant non-small cell lung cancer (NSCLC) on September 15, 2026. The data, with a May 12, 2026, cutoff and efficacy follow-up through August 10, 2026, showed an objective response rate of 45% and a disease control rate of 88% among 40 patients with EGFR C797S-positive resistance. This positive news regarding its lead program, designed to overcome limitations of existing EGFR inhibitors, contributed to an over 18% stock surge on September 16, 2026.

2. FDA Fast Track Designation for BH-30643.

The company received FDA Fast Track Designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC, which was announced prior to the updated clinical trial results. This designation from the U.S. Food and Drug Administration facilitates expedited development and review for therapies addressing serious conditions and unmet medical needs, signaling regulatory confidence in the drug's potential.

Show more
Updated on 9/16/2026

BlossomHill Therapeutics (BLSM) stock has gained about 70% since it went public on 8/7/2026 because of the following key factors:

1. Positive Clinical Trial Data for Lead Candidate BH-30643.

BlossomHill Therapeutics announced encouraging updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant non-small cell lung cancer (NSCLC) on September 15, 2026. The data, with a May 12, 2026, cutoff and efficacy follow-up through August 10, 2026, showed an objective response rate of 45% and a disease control rate of 88% among 40 patients with EGFR C797S-positive resistance. This positive news regarding its lead program, designed to overcome limitations of existing EGFR inhibitors, contributed to an over 18% stock surge on September 16, 2026.

2. FDA Fast Track Designation for BH-30643.

The company received FDA Fast Track Designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC, which was announced prior to the updated clinical trial results. This designation from the U.S. Food and Drug Administration facilitates expedited development and review for therapies addressing serious conditions and unmet medical needs, signaling regulatory confidence in the drug's potential.

3. Strong Analyst Coverage and Positive Price Targets.

Shortly after its IPO, BlossomHill Therapeutics received favorable coverage from multiple investment analysts. In early September 2026, firms such as H.C. Wainwright, Lifesci Capital, Guggenheim, and JPMorgan Chase & Co. initiated coverage with "Buy," "Outperform," or "Overweight" ratings. Analysts set price targets ranging from $28.00 to $35.00, contributing to an average consensus price target of $32.20 and a "Moderate Buy" rating for the stock.

4. Significant Insider Buying Post-IPO.

Insiders demonstrated strong confidence in the company by making substantial share purchases following the IPO. On August 10, 2026, Director Carl Gordon purchased 625,000 shares for a total of $10,000,000.00. Additionally, Director Bihua Chen acquired 312,500 shares valued at $5,000,000.00 on the same date. Total insider buying over the past three months amounted to approximately $25.2 million, with no reported insider selling, indicating strong internal belief in BlossomHill Therapeutics' prospects.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

5/31/2026 to 9/21/2026
ReturnCorrelation
BLSM  
Market (SPY)2.5%10.7%
Sector (XLV)13.1%-0.1%

Fundamental Drivers

null
null

Market Drivers

2/28/2026 to 9/21/2026
ReturnCorrelation
BLSM  
Market (SPY)13.4%10.7%
Sector (XLV)5.9%-0.1%

Fundamental Drivers

null
null

Market Drivers

8/31/2025 to 9/21/2026
ReturnCorrelation
BLSM  
Market (SPY)21.2%10.7%
Sector (XLV)24.6%-0.1%

Fundamental Drivers

null
null

Market Drivers

8/31/2023 to 9/21/2026
ReturnCorrelation
BLSM  
Market (SPY)78.3%10.7%
Sector (XLV)32.8%-0.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
BLSM Return-----61%61%
Peers Return30%14%-0%7%24%20%133%
S&P 500 Return27%-19%24%23%16%12%104%

Monthly Win Rates [3]
BLSM Win Rate-----100% 
Peers Win Rate53%62%42%50%58%60% 
S&P 500 Win Rate75%42%67%75%67%44% 

Max Drawdowns [4]
BLSM Max Drawdown------ 
Peers Max Drawdown-18%-17%-27%-21%-23%-16% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, BMY, PFE, AMGN, LLY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/21/2026 (YTD)

How Low Can It Go

BLSM has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to JNJ, BMY, PFE, AMGN, LLY

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

BLSM has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to JNJ, BMY, PFE, AMGN, LLY

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About BlossomHill Therapeutics (BLSM)

N/A

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

J. Jean Cui, Ph.D. Scientific Founder, President, and CEO

Dr. J. Jean Cui is the scientific founder, President, and CEO of BlossomHill Therapeutics. She was also the scientific founder and Chief Scientific Officer of Turning Point Therapeutics, Inc., an oncology biotech company that went public on NASDAQ in April 2019 (TPTX) and was subsequently acquired by Bristol Myers Squibb for $4.1 billion in August 2022. Prior to co-founding Turning Point, Dr. Cui served as a senior principal scientist and associate research fellow at Pfizer and held project and group leader roles at SUGEN, Inc., a Pharmacia Corporation. She is a lead inventor of three FDA-approved targeted cancer therapies: repotrectinib (AUGTYRO®), crizotinib (XALKORI®), and lorlatinib (LORBRENA®).

Jason Keyes, MBA Executive Vice President and Chief Financial Officer

Jason Keyes serves as the Executive Vice President and Chief Financial Officer of BlossomHill Therapeutics. Before joining BlossomHill, Mr. Keyes was the chief financial officer of Equillium, Inc. for over seven years, and also previously served as chief financial officer of Orexigen Therapeutics, Inc. His career spans nearly 25 years in the biotechnology industry, including various corporate finance and strategic planning positions at Amylin Pharmaceuticals, Inc., Amgen, Inc., and Baxter Healthcare Corporation. BlossomHill Therapeutics is a privately-held company supported by leading investors including Cormorant Asset Management, OrbiMed, and Vivo Capital.

Y. Peter Li, Ph.D., MBA Co-Founder and Executive Chairman

Dr. Y. Peter Li is a Co-Founder and the Executive Chairman of BlossomHill Therapeutics. He co-founded Turning Point Therapeutics, Inc. with Dr. J. Jean Cui, which was acquired by Bristol Myers Squibb for $4.1 billion in 2022.

Geoff Oxnard, M.D. Executive Vice President and Chief Medical Officer

Dr. Geoff Oxnard serves as the Executive Vice President and Chief Medical Officer of BlossomHill Therapeutics.

Vincent Liptak, J.D., Ph.D., MBA Executive Vice President and General Counsel

Dr. Vincent Liptak is the Executive Vice President and General Counsel of BlossomHill Therapeutics.

AI Analysis | Feedback

BlossomHill Therapeutics (BLSM) faces several key risks inherent to its nature as a clinical-stage biopharmaceutical company focused on oncology.

  1. Clinical Development and Regulatory Approval Risk: As a clinical-stage company, BlossomHill's success is heavily contingent on its ability to successfully develop its product candidates through various clinical trial phases and ultimately secure regulatory approval. The company's lead candidate, BH-30643, is in a global Phase 1/2 clinical trial, while BH-30236 is in Phase 1, and BH-501284 is in the preclinical stage. There is no guarantee that any of these candidates will demonstrate sufficient safety and efficacy to gain approval from regulatory bodies like the FDA. The S-1 filing highlights that the field of precision medicine for genetically defined cancers is "rapidly evolving and scientifically uncertain," and the company's approach "may never lead to marketable products."
  2. Intense Competition: BlossomHill operates in highly competitive oncology markets. Its lead product candidate, BH-30643, an OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC), is entering a field with established competitors such as AstraZeneca's Tagrisso and Johnson & Johnson's Rybrevant. Numerous other companies are also developing rival therapies for EGFR-mutant NSCLC. Similarly, its preclinical pan-KRAS inhibitor, BH-501284, faces competition from other companies further along in development, such as Revolution Medicines. This competition could limit market penetration and commercial success even if BlossomHill's products receive approval.
  3. Funding and Commercialization Risk: As a development-stage company, BlossomHill Therapeutics does not currently generate product revenue and reported a net loss of $60.6 million in 2025. The company relies on external funding, such as its recent initial public offering (IPO), to finance its ongoing clinical trials and operations. Should BlossomHill's product candidates receive regulatory approval, the company would then face the significant challenge and cost of commercialization, including market acceptance, pricing, and securing reimbursement, without a prior track record of successful product launches. The S-1 filing also notes that "we may lack adequate funding to initiate or continue one or more of our clinical trials."

AI Analysis | Feedback

null

AI Analysis | Feedback

BlossomHill Therapeutics (BLSM) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer. The company's pipeline includes several product candidates targeting various cancers.

For its lead product candidate, BH-30643, an OMNI-EGFR inhibitor in a global Phase 1/2 trial for EGFR-mutant non-small cell lung cancer (NSCLC), the worldwide addressable market for EGFR medicines was approximately $8.0 billion in 2025 and is projected to exceed $13.4 billion by 2030.

Information regarding the specific addressable market sizes for BlossomHill's other main product candidates, BH-30236 (a CLK inhibitor for relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS)) and BH-501284 (a preclinical pan-KRAS inhibitor), is not readily available in the provided search results.

AI Analysis | Feedback

BlossomHill Therapeutics (BLSM) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer treatment. As the company is currently in the clinical stage and has recently filed for an Initial Public Offering (IPO), its future revenue growth over the next 2-3 years will primarily be driven by the advancement and potential commercialization of its pipeline products.

The key expected drivers of future revenue growth for BlossomHill Therapeutics include:

  1. Advancement and potential accelerated approval of BH-30643 in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC): BH-30643, an OMNI-EGFR inhibitor, is BlossomHill's most advanced product candidate and is currently in a global Phase 1/2 clinical trial (SOLARA) for EGFR-mutant NSCLC. The company plans to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 to discuss recommended Phase 2 dosing and a potential accelerated approval pathway, particularly for patients with C797S-positive EGFR-mutant NSCLC, an area with significant unmet medical need. Dosing of the first patient in a pivotal Phase 2 trial is anticipated in the first quarter of 2027. The worldwide market for EGFR medicines was estimated at $8.0 billion in 2025 and is projected to exceed $13.4 billion by 2030, indicating a substantial market opportunity.
  2. Progression of BH-30236 through clinical development for Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS): BH-30236, a CLK inhibitor, is currently undergoing a Phase 1 clinical trial in patients with relapsed or refractory AML and higher-risk MDS. Positive safety and efficacy data from this ongoing trial, expected to be reported in the first half of 2027, and its subsequent advancement into later-stage clinical trials, would be a significant driver for future revenue. The trial is evaluating BH-30236 as a monotherapy and in combination with venetoclax, the standard of care.
  3. Initiation of clinical trials for BH-501284 (pan-KRAS inhibitor): BlossomHill also has a preclinical pan-KRAS inhibitor, BH-501284, which targets KRAS-driven cancers. The company intends to advance this preclinical asset into clinical testing in early 2027. Moving this candidate into the clinic would expand BlossomHill's pipeline into another significant oncology market, demonstrating pipeline progression and offering additional future revenue potential.

AI Analysis | Feedback


Share Issuance

  • BlossomHill Therapeutics filed for an initial public offering (IPO) in July 2026, aiming to raise up to $100 million.
  • The company plans to list its common stock on the Nasdaq Global Select Market under the symbol "BLSM."

Inbound Investments

  • Since its founding in 2020, BlossomHill Therapeutics has raised over $257 million in private capital.
  • In February 2024, the company had raised a total of $173 million from investors, including Colt Ventures, Cormorant Asset Management, and OrbiMed.
  • An $84 million Series B extension financing round closed in December 2025, bringing the total capital raised to $257 million, with participation from new investors such as Janus Henderson Investors, Brahma Capital, and BioTrack Capital, alongside existing investors.

Capital Expenditures

  • A portion of the net proceeds from the upcoming IPO is intended for capital expenditures, working capital, and other general corporate purposes.
  • The company's San Diego, CA headquarters consists of approximately 46,300 sq ft of office and lab space, leased through 2035.
  • The primary focus for capital allocation, including future capital expenditures, is to advance the clinical development of its drug candidates (BH-30643, BH-30236, and BH-501284).

Peer Outperformance in Biotechnology

null
Share of Biotechnology constituents that BLSM has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
insufficient peer history
3Y
insufficient peer history
5Y
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is BLSM's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 17.8%45.5%92.1% CAH 393% · MCK 348% · COR 173%
Managed Health Care 8 41.5%-4.6%2.2% OSCR 80% · HQY 52% · ELV 17%
Health Care Services 20 21.2%36.3%-1.7% HIMS 256% · RDNT 156% · DGX 77%
Health Care Facilities 24 6.4%8.0%-5.7% NHC 273% · THC 256% · ENSG 129%
Health Care Equipment 50 -0.5%-1.0%-21.7% POCI 11025% · UFPT 345% · GKOS 215%
Pharmaceuticals 62 -10.5%12.0%-36.3% LQDA 2281% · INDV 1104% · ETON 1006%
Health Care Supplies 12 14.9%-9.0%-39.5% LNTH 282% · HAE 58% · MMSI 19%
Life Sciences Tools & Services 109 6.3%-9.6%-67.8% SNWV 1712% · MEDP 227% · NTRA 195%
Biotechnology ← 367 0.0%-22.7%-79.2% CELZ 1336% · DNTH 1214% · ELVN 1055%
Health Care Technology 21 -25.8%-50.7%-79.4% SPOK 69% · HSTM 2% · VEEV -12%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

BLSMJNJBMYPFEAMGNLLYMedian
NameBlossomH.Johnson .Bristol-.Pfizer Amgen Eli Lilly 
Mkt Price26.80269.4762.6227.74393.161,164.89166.05
Mkt Cap-648.7127.9158.1212.31,039.5212.3
Rev LTM097,92949,18763,69538,09579,66656,441
Op Inc LTM-7226,25613,84217,01911,42639,60815,430
FCF LTM-6522,22811,44010,98510,17513,56011,212
FCF 3Y Avg-19,48612,9889,4118,7543,2949,411
CFO LTM-6427,60812,78213,40112,47828,08313,092
CFO 3Y Avg-25,09314,28212,19810,31214,51014,282

Growth & Margins

BLSMJNJBMYPFEAMGNLLYMedian
NameBlossomH.Johnson .Bristol-.Pfizer Amgen Eli Lilly 
Rev Chg LTM-8.1%3.1%-0.2%9.1%49.6%8.1%
Rev Chg 3Y Avg-6.0%2.9%-5.2%12.8%39.4%6.0%
Rev Chg Q-6.6%5.7%2.6%9.5%47.7%6.6%
QoQ Delta Rev Chg LTM-1.6%1.5%0.6%2.4%10.3%1.6%
Op Inc Chg LTM-21.4%39.1%2.1%39.5%76.5%39.1%
Op Inc Chg 3Y Avg-6.7%22.3%233.9%12.3%71.3%22.3%
Op Mgn LTM-26.8%28.1%26.7%30.0%49.7%28.1%
Op Mgn 3Y Avg-25.6%21.4%18.7%24.5%42.1%24.5%
QoQ Delta Op Mgn LTM-0.0%0.1%-0.5%1.6%2.4%0.1%
CFO/Rev LTM-28.2%26.0%21.0%32.8%35.3%28.2%
CFO/Rev 3Y Avg-27.4%29.9%19.7%29.3%22.5%27.4%
FCF/Rev LTM-22.7%23.3%17.2%26.7%17.0%22.7%
FCF/Rev 3Y Avg-21.2%27.2%15.1%24.9%2.5%21.2%

Valuation

BLSMJNJBMYPFEAMGNLLYMedian
NameBlossomH.Johnson .Bristol-.Pfizer Amgen Eli Lilly 
Mkt Cap-648.7127.9158.1212.31,039.5212.3
P/S-6.62.62.55.613.05.6
P/Op Inc-24.79.29.318.626.218.6
P/EBIT-24.89.422.916.425.222.9
P/E-30.813.836.524.338.930.8
P/CFO-23.510.011.817.037.017.0
Total Yield-5.2%11.2%8.9%6.6%3.1%6.6%
Dividend Yield-1.9%4.0%6.2%2.5%0.6%2.5%
FCF Yield 3Y Avg-4.6%13.5%6.7%5.2%0.3%5.2%
D/E-0.10.40.40.30.10.3
Net D/E-0.00.30.30.20.00.2

Returns

BLSMJNJBMYPFEAMGNLLYMedian
NameBlossomH.Johnson .Bristol-.Pfizer Amgen Eli Lilly 
1M Rtn63.6%0.2%-6.6%-1.2%-10.5%-7.2%-3.9%
3M Rtn67.5%17.1%15.8%12.5%14.7%5.9%15.2%
6M Rtn67.5%15.7%12.2%7.2%13.9%28.3%14.8%
12M Rtn67.5%56.4%45.8%23.5%41.6%55.9%50.8%
3Y Rtn67.5%82.8%22.4%2.9%60.7%116.0%64.1%
1M Excs Rtn68.0%-0.3%-6.0%-1.8%-10.4%-8.0%-3.9%
3M Excs Rtn63.6%13.2%11.9%8.6%10.8%1.9%11.3%
6M Excs Rtn48.2%-3.6%-8.0%-13.0%-4.8%9.5%-4.2%
12M Excs Rtn50.4%41.1%26.8%5.8%29.4%36.6%33.0%
3Y Excs Rtn-4.9%6.9%-51.1%-73.8%-8.4%28.6%-6.6%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024
Business of designing and developing novel small molecule product candidates00
Total00


Net Income by Segment
$ Mil20252024
Business of designing and developing novel small molecule product candidates-61-31
Total-61-31


Price Behavior

null
BLSM Betas & Captures as of 8/31/2026

 1M2M3M6M1Y3Y
Beta-1.720.350.54-0.150.77-2.02
Up Beta-3.04-7.178.86-2.88-4.925.76
Down Beta2.473.13-3.67-0.09-1.23-0.59
Up Capture415%199%116%44%20%2%
Bmk +ve Days10213268138427
Stock +ve Days888888
Down Capture277%106%57%33%21%11%
Bmk -ve Days11213259113324
Stock -ve Days888888

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BLSM
BLSM67.8%85.0%5.47-
Sector ETF (XLV)24.6%16.1%1.17-0.1%
Equity (SPY)18.2%13.0%1.0110.7%
Gold (GLD)18.8%29.3%0.59-8.8%
Commodities (DBC)47.0%20.6%1.76-35.1%
Real Estate (VNQ)5.7%13.6%0.15-2.8%
Bitcoin (BTCUSD)-31.0%44.4%-0.71-10.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BLSM
BLSM10.9%85.0%5.47-
Sector ETF (XLV)6.6%15.2%0.25-0.1%
Equity (SPY)13.1%17.2%0.5810.7%
Gold (GLD)18.9%18.8%0.81-8.8%
Commodities (DBC)11.0%19.5%0.44-35.1%
Real Estate (VNQ)1.2%18.8%-0.04-2.8%
Bitcoin (BTCUSD)12.5%52.6%0.42-10.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BLSM
BLSM5.3%85.0%5.47-
Sector ETF (XLV)10.8%16.7%0.53-0.1%
Equity (SPY)15.6%17.9%0.7410.7%
Gold (GLD)12.1%16.4%0.61-8.8%
Commodities (DBC)8.4%18.1%0.38-35.1%
Real Estate (VNQ)4.9%20.7%0.20-2.8%
Bitcoin (BTCUSD)62.7%66.2%1.03-10.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date8312026
Short Interest: Shares Quantity0.1 Mil
Short Interest: % Change Since 8152026-1.0%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity29.1 Mil
Short % of Basic Shares0.4%

Earnings Returns History

Updated 9/22/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
9/18/2026-4.0%  
SUMMARY STATS   
# Positive000
# Negative100
Median Positive   
Median Negative-4.0%  
Max Positive   
Max Negative-4.0%  
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
9/18/2026-4.0%  
SUMMARY STATS   
# Positive000
# Negative100
Median Positive   
Median Negative-4.0%  
Max Positive   
Max Negative-4.0%  

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202609/18/202610-Q
03/31/202608/07/2026424B4
Collapse to Preview
Report DateFiling DateFiling
06/30/202609/18/202610-Q
03/31/202608/07/2026424B4

Insider Activity

Updated 8/12/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gordon, Carl LSee footnotesBuy812202616.00625,00010,000,00043,428,464Form
2Orbimed, Advisors LlcSee footnotesBuy812202616.00625,00010,000,00043,428,464Form
3Schmid, John PDirectBuy810202616.006,00096,00096,000Form
4Chen, BihuaSee footnotesBuy810202616.00312,5005,000,00057,824,544Form
5Keyes, Jason AChief Financial OfficerDirectBuy810202616.0070011,20011,200Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gordon, Carl LSee footnotesBuy812202616.00625,00010,000,00043,428,464Form
2Orbimed, Advisors LlcSee footnotesBuy812202616.00625,00010,000,00043,428,464Form
3Schmid, John PDirectBuy810202616.006,00096,00096,000Form
4Chen, BihuaSee footnotesBuy810202616.00312,5005,000,00057,824,544Form
5Keyes, Jason AChief Financial OfficerDirectBuy810202616.0070011,20011,200Form
6Liptak, Vincent PaulGeneral CounselDirectBuy810202616.002,20035,2001,782,592Form
7Liptak, Vincent PaulGeneral CounselDirectBuy810202615.802,50039,5001,725,550Form
Core Cache Last Updated: 9/21/2026